

To: Colmer, Robert W SC-DCS/18 <Rob.Colmer@shell.com>
From: Clegg, Patsy M SCC-DCS/22
</O=SHELL/OU=MSXSCC/CN=RECIPIENTS/CN=PH197432>
Cc:
Bcc:
Received Date: 2007-04-18 13:47:45 GMT
Subject: FW: Shanghai Health Study Update

-----Original Message-----

From: Clegg, Patsy M SCC-DCS/22
Sent: Tuesday, April 17, 2007 9:41 AM
To: Methvin, Stacy P SCC-DCA; Williams, Charlie CR SIEP-EPT-RL; Simpson, Edward J SCC-DCA/2
Cc: Snyder, Phil J SDIUS-DXX/9; Sykes, Paul B SCC-DCS/23; Williams, Elizabeth J SCAI-DCS/22;
Cagen, Stuart Z SHLOIL-SHOIL-SHS; Tsai, Shan P SHLOIL-SHS; Semmler, Klaus K DSC-DCS/235
Subject: Shanghai Health Study Update

Progress is being made towards establishing a new contract with CinPathogen and extending the University of Colorado grant to support finishing the Shanghai Health Study. Key issues include providing advance funding to keep the lab operating while new contracts are being established and developing specific deliverables and timelines for the new contract and grant. All sponsors have executed contract amendment 4 agreeing to additional funding.

Timeline for the study:	June 30 07	End AML case accrual
case accrual	December 31 07	End lymphoid neoplasms (formerly NHL)
will continue beyond 08)	2008	Data analysis and publications (some publications
	December 31 08	Study ends; consortium disbands

Key events are listed below.

April 11: API Executive Committee reached consensus on
(1) supporting the advance of \$800K to Dr. Irons providing that he agrees to certain
terms. No additional funds until contract is in place. Attached is the letter that Red
Cavaney sent to Dr. Irons.

(2) funding through CinPathogen conditional on all API contract criteria being met.

The draft list of action items from the meeting:

April 16: Dr. Irons signed letter. API wired \$800K to CinPathogen. Irons signed letter on April 12; IT challenges in transmitting to API.

Consortium conference call to further develop list of deliverables to support items in
Irons/API letter. API has discussed with Irons, so understanding and agreement
can be more quickly achieved.

April 26 Consortium call scheduled to finalize deliverables and get up update on API
contracting criteria being met.

I will keep you updated. Happy to address any questions or comments.

Patsy Clegg

SHELL-MCCLURG-060475

Product Steward
Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 2521 Fax: 3325
Email: patsy.clegg@shell.com
Internet: <http://www.shell.com/chemicals>

Attachments:

41107_RCLettertoRlrons.pdf
Action Items - draft.ZIP